137 related articles for article (PubMed ID: 37890647)
1. Development of long-acting injectable suspensions by continuous antisolvent crystallization: An integrated bottom-up process.
Nandi S; Padrela L; Tajber L; Collas A
Int J Pharm; 2023 Dec; 648():123550. PubMed ID: 37890647
[TBL] [Abstract][Full Text] [Related]
2. Continuous Microfluidic Antisolvent Crystallization as a Bottom-Up Solution for the Development of Long-Acting Injectable Formulations.
Nandi S; Verstrepen L; Hugo Silva M; Padrela L; Tajber L; Collas A
Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543270
[TBL] [Abstract][Full Text] [Related]
3. Bottom-up production of injectable itraconazole suspensions using membrane technology.
Anjum F; Viville T; Nandi S; Wessner M; De Witte B; Collas A; Sadowski G
Int J Pharm; 2024 Apr; 654():123977. PubMed ID: 38458403
[TBL] [Abstract][Full Text] [Related]
4. Characterization and pharmacokinetic study of itraconazole solid dispersions prepared by solvent-controlled precipitation and spray-dry methods.
Sim T; Lim C; Lee JW; Kim DW; Kim Y; Kim M; Choi S; Choi HG; Lee ES; Kim KS; Kang W; Oh KT
J Pharm Pharmacol; 2017 Dec; 69(12):1707-1715. PubMed ID: 28872678
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Solid Dispersion of Itraconazole Prepared by Solubilization in Concentrated Aqueous Solutions of Weak Organic Acids and Drying.
Parikh T; Sandhu HK; Talele TT; Serajuddin AT
Pharm Res; 2016 Jun; 33(6):1456-71. PubMed ID: 26951566
[TBL] [Abstract][Full Text] [Related]
6. Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties.
Duret C; Wauthoz N; Sebti T; Vanderbist F; Amighi K
Int J Pharm; 2012 May; 428(1-2):103-13. PubMed ID: 22414388
[TBL] [Abstract][Full Text] [Related]
7. Preparation of concentrated stable fenofibrate suspensions via liquid antisolvent precipitation.
Azad MA; Knieke C; To D; Davé R
Drug Dev Ind Pharm; 2014 Dec; 40(12):1693-703. PubMed ID: 24102617
[TBL] [Abstract][Full Text] [Related]
8. Single-step preparation and deagglomeration of itraconazole microflakes by supercritical antisolvent method for dissolution enhancement.
Sathigari SK; Ober CA; Sanganwar GP; Gupta RB; Babu RJ
J Pharm Sci; 2011 Jul; 100(7):2952-65. PubMed ID: 21344415
[TBL] [Abstract][Full Text] [Related]
9. In vitro dissolution enhancement of micronized l-nimodipine by antisolvent re-crystallization from its crystal form H.
Zu Y; Li N; Zhao X; Li Y; Ge Y; Wang W; Wang K; Liu Y
Int J Pharm; 2014 Apr; 464(1-2):1-9. PubMed ID: 24456674
[TBL] [Abstract][Full Text] [Related]
10. A Systematic Approach to the Development of Cilostazol Nanosuspension by Liquid Antisolvent Precipitation (LASP) and Its Combination with Ultrasound.
Jakubowska E; Milanowski B; Lulek J
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830298
[TBL] [Abstract][Full Text] [Related]
11. Comparative assessment of solubility enhancement of itroconazole by solid dispersion and co-crystallization technique: Investigation of simultaneous effect of media composition on drug dissolution.
Rajbhar K; Karodadeo GR; Kumar V; Barethiya V; Lahane A; Kale S; Thakre V; Dixit G; Kohale N; Hiradeve S; Rarokar NR
Ann Pharm Fr; 2023 Sep; 81(5):843-855. PubMed ID: 37182590
[TBL] [Abstract][Full Text] [Related]
12. Impact of Formulation Parameters on In Vitro Release from Long-Acting Injectable Suspensions.
Bao Q; Zou Y; Wang Y; Choi S; Burgess DJ
AAPS J; 2021 Mar; 23(2):42. PubMed ID: 33709196
[TBL] [Abstract][Full Text] [Related]
13. Incorporation of itraconazole nano-co-crystals into multiparticulate oral dosage forms.
Huang Z; Staufenbiel S; Bodmeier R
Eur J Pharm Biopharm; 2022 Jul; 176():75-86. PubMed ID: 35598769
[TBL] [Abstract][Full Text] [Related]
14. New inhalation-optimized itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis.
Duret C; Wauthoz N; Sebti T; Vanderbist F; Amighi K
Int J Nanomedicine; 2012; 7():5475-89. PubMed ID: 23093903
[TBL] [Abstract][Full Text] [Related]
15. Increased dissolution and oral absorption of itraconazole/Soluplus extrudate compared with itraconazole nanosuspension.
Zhang K; Yu H; Luo Q; Yang S; Lin X; Zhang Y; Tian B; Tang X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1285-92. PubMed ID: 23562534
[TBL] [Abstract][Full Text] [Related]
16. Enhanced pulmonary absorption of poorly soluble itraconazole by micronized cocrystal dry powder formulations.
Karashima M; Sano N; Yamamoto S; Arai Y; Yamamoto K; Amano N; Ikeda Y
Eur J Pharm Biopharm; 2017 Jun; 115():65-72. PubMed ID: 28223260
[TBL] [Abstract][Full Text] [Related]
17. Ternary Amorphous Solid Dispersions Containing a High-Viscosity Polymer and Mesoporous Silica Enhance Dissolution Performance†.
Hanada M; Jermain SV; Thompson SA; Furuta H; Fukuda M; Williams RO
Mol Pharm; 2021 Jan; 18(1):198-213. PubMed ID: 33291881
[TBL] [Abstract][Full Text] [Related]
18. Influence of formulation and processing variables on properties of itraconazole nanoparticles made by advanced evaporative precipitation into aqueous solution.
Bosselmann S; Nagao M; Chow KT; Williams RO
AAPS PharmSciTech; 2012 Sep; 13(3):949-60. PubMed ID: 22752680
[TBL] [Abstract][Full Text] [Related]
19. Effect of hydrophilic additives on the dissolution and pharmacokinetic properties of itraconazole-enteric polymer hot-melt extruded amorphous solid dispersions.
Lang B; Liu S; McGinity JW; Williams RO
Drug Dev Ind Pharm; 2016; 42(3):429-45. PubMed ID: 26355819
[TBL] [Abstract][Full Text] [Related]
20. Tailoring the use of excipients in bottom-up production of naproxen crystal suspensions via membrane technology.
Anjum F; Wessner M; De Witte B; Al-Rifai N; Collas A; Sadowski G
Int J Pharm; 2024 Mar; 652():123846. PubMed ID: 38272195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
